164 related articles for article (PubMed ID: 18222088)
1. Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors.
Cullen MD; Cheung YF; Houslay MD; Hartman TL; Watson KM; Buckheit RW; Pannecouque C; De Clercq E; Cushman M
Bioorg Med Chem Lett; 2008 Feb; 18(4):1530-3. PubMed ID: 18222088
[TBL] [Abstract][Full Text] [Related]
2. The biological effects of structural variation at the meta position of the aromatic rings and at the end of the alkenyl chain in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors.
Xu G; Micklatcher M; Silvestri MA; Hartman TL; Burrier J; Osterling MC; Wargo H; Turpin JA; Buckheit RW; Cushman M
J Med Chem; 2001 Nov; 44(24):4092-113. PubMed ID: 11708913
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, anti-HIV activities, and metabolic stabilities of alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors.
Silvestri MA; Nagarajan M; De Clercq E; Pannecouque C; Cushman M
J Med Chem; 2004 Jun; 47(12):3149-62. PubMed ID: 15163195
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability.
Cullen MD; Deng BL; Hartman TL; Watson KM; Buckheit RW; Pannecouque C; Clercq ED; Cushman M
J Med Chem; 2007 Oct; 50(20):4854-67. PubMed ID: 17803290
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and anti-HIV activity of new alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors (NNRTIs) incorporating benzoxazolone and benzisoxazole rings.
Deng BL; Cullen MD; Zhou Z; Hartman TL; Buckheit RW; Pannecouque C; De Clercq E; Fanwick PE; Cushman M
Bioorg Med Chem; 2006 Apr; 14(7):2366-74. PubMed ID: 16321539
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of tubulin polymerization by select alkenyldiarylmethanes.
Cullen MD; Sarkar T; Hamel E; Hartman TL; Watson KM; Buckheit RW; Pannecouque C; De Clercq E; Cushman M
Bioorg Med Chem Lett; 2008 Jan; 18(2):469-73. PubMed ID: 18083556
[TBL] [Abstract][Full Text] [Related]
7. Systematic evaluation of methyl ester bioisosteres in the context of developing alkenyldiarylmethanes (ADAMs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) for anti-HIV-1 chemotherapy.
Hoshi A; Sakamoto T; Takayama J; Xuan M; Okazaki M; Hartman TL; Buckheit RW; Pannecouque C; Cushman M
Bioorg Med Chem; 2016 Jul; 24(13):3006-3022. PubMed ID: 27234889
[TBL] [Abstract][Full Text] [Related]
8. Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors.
Casimiro-Garcia A; Micklatcher M; Turpin JA; Stup TL; Watson K; Buckheit RW; Cushman M
J Med Chem; 1999 Nov; 42(23):4861-74. PubMed ID: 10579849
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of alkenyldiarylmethane (ADAM) non-nucleoside HIV-1 reverse transcriptase inhibitors with non-identical aromatic rings.
Xu G; Hartman TL; Wargo H; Turpin JA; Buckheit RW; Cushman M
Bioorg Med Chem; 2002 Feb; 10(2):283-90. PubMed ID: 11741777
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, anti-HIV activity, and metabolic stability of new alkenyldiarylmethane HIV-1 non-nucleoside reverse transcriptase inhibitors.
Deng BL; Hartman TL; Buckheit RW; Pannecouque C; De Clercq E; Fanwick PE; Cushman M
J Med Chem; 2005 Sep; 48(19):6140-55. PubMed ID: 16162014
[TBL] [Abstract][Full Text] [Related]
11. Solid-phase synthesis of the alkenyldiarylmethane (ADAM) series of non-nucleoside HIV-1 reverse transcriptase inhibitors.
Xu G; Loftus TL; Wargo H; Turpin JA; Buckheit RW; Cushman M
J Org Chem; 2001 Sep; 66(18):5958-64. PubMed ID: 11529718
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and anti-HIV activity of new metabolically stable alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors incorporating N-methoxy imidoyl halide and 1,2,4-oxadiazole systems.
Sakamoto T; Cullen MD; Hartman TL; Watson KM; Buckheit RW; Pannecouque C; De Clercq E; Cushman M
J Med Chem; 2007 Jul; 50(14):3314-21. PubMed ID: 17579385
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of certain alkenyldiarylmethanes as anti-HIV-1 agents which act as non-nucleoside reverse transcriptase inhibitors.
Cushman M; Golebiewski WM; Graham L; Turpin JA; Rice WG; Fliakas-Boltz V; Buckheit RW
J Med Chem; 1996 Aug; 39(16):3217-27. PubMed ID: 8759644
[TBL] [Abstract][Full Text] [Related]
14. Crystallographic study of a novel subnanomolar inhibitor provides insight on the binding interactions of alkenyldiarylmethanes with human immunodeficiency virus-1 reverse transcriptase.
Cullen MD; Ho WC; Bauman JD; Das K; Arnold E; Hartman TL; Watson KM; Buckheit RW; Pannecouque C; De Clercq E; Cushman M
J Med Chem; 2009 Oct; 52(20):6467-73. PubMed ID: 19775161
[TBL] [Abstract][Full Text] [Related]
15. New alkenyldiarylmethanes with enhanced potencies as anti-HIV agents which act as non-nucleoside reverse transcriptase inhibitors.
Cushman M; Casimiro-Garcia A; Hejchman E; Ruell JA; Huang M; Schaeffer CA; Williamson K; Rice WG; Buckheit RW
J Med Chem; 1998 Jun; 41(12):2076-89. PubMed ID: 9622549
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, biological activity, pharmacokinetic properties and molecular modelling studies of novel 1H,3H-oxazolo[3,4-a]benzimidazoles: non-nucleoside HIV-1 reverse transcriptase inhibitors.
Chimirri A; Monforte P; Rao A; Zappalà M; Monforte AM; De Sarro G; Pannecouque C; Witvrouw M; Balzarini J; De Clercq E
Antivir Chem Chemother; 2001 May; 12(3):169-74. PubMed ID: 12959325
[TBL] [Abstract][Full Text] [Related]
17. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E
Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of alkenyldiarylmethanes (ADAMs) containing benzo[d]isoxazole and oxazolidin-2-one rings, a new series of potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
Deng BL; Zhao Y; Hartman TL; Watson K; Buckheit RW; Pannecouque C; De Clercq E; Cushman M
Eur J Med Chem; 2009 Mar; 44(3):1210-4. PubMed ID: 18952324
[TBL] [Abstract][Full Text] [Related]
19. Replacement of the metabolically labile methyl esters in the alkenyldiarylmethane series of non-nucleoside reverse transcriptase inhibitors with isoxazolone, isoxazole, oxazolone, or cyano substituents.
Deng BL; Hartman TL; Buckheit RW; Pannecouque C; De Clercq E; Cushman M
J Med Chem; 2006 Aug; 49(17):5316-23. PubMed ID: 16913721
[TBL] [Abstract][Full Text] [Related]
20. Hydrolysis of thioesters in an ion trap.
Cullen M; Miles D; Rothwell A; Bonham C; Wood KV; Cushman M
Rapid Commun Mass Spectrom; 2008 Apr; 22(8):1094-8. PubMed ID: 18335465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
